Survival in Renal Cell Carcinoma: Tamoxifen vs Interleukin 2 and Interferon
Author Information
Author(s): R Henriksson, S Nilsson, S Colleen, P WersaII, M HeIsing, R Zimmerman, K Engman
Primary Institution: UmeA University Hospital
Hypothesis
Does the combination of interleukin 2 and interferon-a with tamoxifen improve survival in patients with advanced renal cell carcinoma compared to tamoxifen alone?
Conclusion
The study found no significant survival advantage for the combination treatment compared to tamoxifen alone.
Supporting Evidence
- The interim analysis showed no survival advantage for either treatment group.
- Adverse effects were more pronounced in the IL-2/IFN-a group.
- The median follow-up was 11 months.
- Costs of IL-2/IFN-a treatment were significantly higher than tamoxifen.
Takeaway
Doctors wanted to see if a new treatment could help people with kidney cancer live longer, but it didn't work better than the old treatment.
Methodology
The study was an open, randomized, multicentre trial comparing IL-2 and interferon-a with tamoxifen alone in patients with advanced renal cell carcinoma.
Potential Biases
The study's design and limited sample size may introduce bias in the results.
Limitations
The number of patients included was limited, and the study was stopped early due to lack of survival advantage.
Participant Demographics
Patients had histologically documented metastatic renal cell carcinoma, aged 18-75, with a performance status of WHO 0-2.
Want to read the original?
Access the complete publication on the publisher's website